Novel Treatments Compared to Traditional Therapies in Managing Childhood Eczema in Terms of Efficacy and Safety

ABSTRACT Background Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder that often begins in early childhood and significantly impacts quality of life. While traditional management has centered on topical corticosteroids, emollients, and calcineurin inhibitors, the therapeutic landscape has rapidly expanded to include systemic immunomodulators, biologics, and targeted small molecules. This literature review aims to compare the efficacy and safety of traditional therapies with emerging treatment options for pediatric AD. Methods A PubMed search identified articles on novel and traditional AD therapies in children ≤ 18 years in terms of safety and efficacy. Results Topical corticosteroids and emollients remain first‐line therapies for mild‐to‐moderate disease, with demonstrated efficacy in reducing inflammation and restoring skin barrier function. Calcineurin inhibitors offer a steroid‐sparing alternative. Newer topical agents like crisaborole (PDE4 inhibitor) and ruxolitinib (JAK1/2 inhibitor) provide targeted anti‐inflammatory effects with favorable safety profiles. For moderate‐to‐severe or refractory cases, systemic therapies—including cyclosporine, methotrexate, and the IL‐4Rα antagonist dupilumab—offer robust disease control. Conclusion While newer therapies demonstrate promising efficacy and tolerability, long‐term safety data in pediatric populations are still evolving. Treatment decisions should be individualized based on disease severity, age, comorbidities, and caregiver preferences. This review synthesizes current evidence to guide clinicians in selecting safe and effective therapies for childhood AD across the disease spectrum. The evidence base for pediatric AD is relatively limited, with much of the available data extrapolated from adult populations. Many trials were short‐term, which does not fully capture the chronic relapsing nature of AD or the long‐term safety of emerging therapies.